# reload+after+2024-01-20 21:46:05.077735
address1§Wagistrasse 14
city§Schlieren
zip§8952
country§Switzerland
phone§41 44 755 77 00
fax§41 44 755 77 07
website§https://www.molecularpartners.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Molecular Partners AG operates as a clinical-stage biopharmaceutical company, develops ankyrin proteins for the treatment of oncology and virology diseases. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular age-related macular degeneration, as well as for diabetic macular edema; and ensovibep (MP0420), a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, a DARPin molecule, which activates T-cells and other immune cells; MP0317, that allows tumor-restricted immune-cell CD40 activation for the treatment of fibroblast activation protein (FAP) positive cancers, which is in Phase I clinical trials; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274, that uses HER2-specific DARPin binding proteins. It also develops MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor (VEGF)and hepatocyte growth factor. Molecular Partners AG has license and research collaboration agreements with Novartis AG to develop DARPin-conjugated radioligand therapies; as well as other third-party collaborators. It also has a collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
fullTimeEmployees§175
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Patrick  Amstutz Ph.D.', 'age': 48, 'title': 'Co-Founder, CEO, Member of Management Board & Director', 'yearBorn': 1975, 'fiscalYear': 2022, 'totalPay': 729870, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Michael Tobias Stumpp Ph.D.', 'age': 51, 'title': 'Co-Founder, Executive VP of Projects & Member of Management Board', 'yearBorn': 1972, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robert  Hendriks', 'title': 'Vice President of Finance', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Alexander  Zurcher', 'age': 48, 'title': 'COO & Member of Management Board', 'yearBorn': 1975, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Renate  Gloggner', 'age': 53, 'title': 'Executive VP of People & Community and Member of Management Board', 'yearBorn': 1970, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Daniel  Steiner Ph.D.', 'title': 'Senior Vice President of Research', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Seth D. Lewis', 'title': 'Senior Vice President of Investor Relations, Communications & Strategy', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Michael  Pitzner', 'title': 'General Counsel, Compliance Officer, Senior VP Legal & Business Development', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Pamela A. Trail Ph.D.', 'age': 67, 'title': 'Strategic Consultant', 'yearBorn': 1956, 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Anne  Goubier D.V.M., Ph.D.', 'title': 'Senior Vice President of Biology', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§0.759
priceToSalesTrailing12Months§16.62945
currency§USD
dateShortInterest§1702598400
forwardEps§-1.87
exchange§NMS
quoteType§EQUITY
shortName§Molecular Partners AG
longName§Molecular Partners AG
firstTradeDateEpochUtc§1623850200
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§3b1227e2-09aa-3330-8282-b0e2c7493dad
gmtOffSetMilliseconds§-18000000
targetHighPrice§16.99
targetLowPrice§6.99
targetMeanPrice§12.0
targetMedianPrice§12.0
recommendationMean§2.7
recommendationKey§hold
numberOfAnalystOpinions§2
quickRatio§14.335
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
